Hikari Power Ltd - AKARI THERAPEUTICS PLC ownership

AKARI THERAPEUTICS PLC's ticker is AKTX and the CUSIP is 00972G108. A total of 14 filers reported holding AKARI THERAPEUTICS PLC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Hikari Power Ltd ownership history of AKARI THERAPEUTICS PLC
ValueSharesWeighting
Q2 2023$22
-8.3%
130,8210.0%0.00%0.0%
Q1 2023$24
-60.7%
130,8210.0%0.00%
-66.7%
Q4 2022$61
-99.9%
130,8210.0%0.01%
-33.3%
Q3 2022$82,000
-37.4%
130,8210.0%0.01%
-35.7%
Q2 2022$131,000
-16.6%
130,8210.0%0.01%0.0%
Q1 2022$157,000
+16.3%
130,821
+45.7%
0.01%
+7.7%
Q4 2021$135,000
-7.5%
89,8150.0%0.01%
-13.3%
Q3 2021$146,000
-5.8%
89,8150.0%0.02%0.0%
Q2 2021$155,000
-34.6%
89,8150.0%0.02%
-40.0%
Q1 2021$237,000
+42.8%
89,8150.0%0.02%
+31.6%
Q4 2020$166,000
+6.4%
89,8150.0%0.02%
-5.0%
Q3 2020$156,000
-95.2%
89,815
-94.0%
0.02%
-95.5%
Q2 2020$3,270,000
+50.3%
1,500,0960.0%0.45%
+45.9%
Q1 2020$2,175,000
-17.1%
1,500,0960.0%0.31%
+12.9%
Q4 2019$2,625,000
+2.3%
1,500,0960.0%0.27%
-1.8%
Q3 2019$2,565,000
-9.3%
1,500,096
+7.1%
0.28%
-9.2%
Q2 2019$2,828,000
-44.8%
1,400,096
-2.1%
0.30%
-43.2%
Q1 2019$5,120,000
+171.8%
1,430,096
+19.2%
0.54%
+153.3%
Q4 2018$1,884,000
-26.4%
1,199,697
+20.0%
0.21%
-18.5%
Q3 2018$2,560,000
+55.5%
1,000,000
+18.5%
0.26%
+43.6%
Q2 2018$1,646,000
+42.1%
843,849
+32.6%
0.18%
+33.1%
Q1 2018$1,158,000
+76.8%
636,343
+320.5%
0.14%
+76.6%
Q4 2017$655,000
-29.5%
151,3340.0%0.08%
-35.8%
Q3 2017$929,000
+235.4%
151,334
+152.2%
0.12%
+224.3%
Q2 2017$277,00060,0120.04%
Other shareholders
AKARI THERAPEUTICS PLC shareholders Q2 2021
NameSharesValueWeighting ↓
SABBY MANAGEMENT, LLC 7,941,867$1,443,0371.26%
Omnia Family Wealth, LLC 782,372$142,1570.11%
NEA Management Company, LLC 452,167$82,1590.01%
Hikari Power Ltd 130,821$240.00%
Bryn Mawr Capital Management, LLC 100,000$18,1700.00%
GEODE CAPITAL MANAGEMENT, LLC 30,264$5,4950.00%
MILLENNIUM MANAGEMENT LLC 261,192$470.00%
Renaissance Technologies 283,550$520.00%
LPL Financial LLC 134,453$24,4300.00%
JPMORGAN CHASE & CO 237$00.00%
View complete list of AKARI THERAPEUTICS PLC shareholders